Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry

International Journal of Pharmaceutics

Volumn 379, Issue 2, 2009, Pages 235-243

  Lalanne, Muriel ^a   Khoury, Hania ^b   Deroussent, Alain ^b   Bosquet, Nathalie ^c   Benech, Henri ^d   Clayette, Pascal ^c   Couvreur, Patrick ^a   Vassal, Gilles ^b   Paci, Angelo ^b   Andrieux, Karine ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d Institut National de la Recherche Agronomique   (France)

Author keywords

Biomimetic model; Didanosine; Glycerolipidic prodrugs; In vitro metabolism; LC MS MS; Lipase

Indexed keywords

2',3' DIDEOXYADENOSINE TRIPHOSPHATE; DIDANOSINE; GLYCEROLIPID; LIPOSOME; PANCREATIN; PHOSPHOLIPASE; PRODRUG; TRIACYLGLYCEROL LIPASE;

ARTICLE; BIOMIMETICS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INTESTINE ABSORPTION; LIPOLYSIS; PHOSPHORYLATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANIMALS; BIOMIMETIC MATERIALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; PRODRUGS;

EID: 69249203589     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.05.030     Document Type: Article

References (38)

1. Alvarez F.J., and Stella V.J. The role of calcium ions and bile salts on the pancreatic lipase-catalyzed hydrolysis of triglyceride emulsions stabilized with lecithin. Pharm. Res. 6 (1989) 449-457
2. Andrieux K., Forte L., Lesieur S., Paternostre M., Ollivon M., and Grabielle-Madelmont C. Insertion and partition of sodiumtaurocholate into egg phosphatidylcholine vesicles. Pharm. Res. 21 (2004) 1505-1516
3. Andrieux K., Forte L., Lesieur S., Paternostre M., Ollivon M., and Grabielle-Madelmont C. Solubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: a model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt. Eur. J. Pharm. Biopharm. 71 (2009) 346-355
4. Aungst B.J. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 39 (1999) 105-116
5. Bangham A.D., Hill H.W., and Miller N.G.A. Preparation and use of liposomes as models of biological membranes. Methods Membr. Biol. 1 (1974) 1-68
6. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C., Rozenbaum W., and Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
7. Becher F., Pruvost A., Goujard C., Guerreiro C., Delfraissy J.F., Grassi J., and Benech H. Improved method for the simultaneous determination of d4T, 3TC and ddI intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16 (2002) 555-565
8. Bonnafe D., Dupraz B., Ughetto-Monfrin J., Namane A., Henin Y., and Dinh T.H. Potential lipophilic nucleotide prodrugs: synthesis, hydolysis, and antiretroviral activity of AZT and d4T acyl nucleotides. J. Org. Chem. 61 (1996) 895-902
9. Bourgeois J., Lalanne M., Pierson L.-A., Marsaud V., Nicolas V., Tsapis N., Ball R., Stanimirovic D., Couvreur P., and Andrieux K. Formulation of glycerolipidic prodrugs into pegylated liposomes for brain delivery. J. Drug Del. Sci. Tech. 19 (2009) 61-66
10. Charman W.N., and Porter C.J.H. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Deliv. Rev. 19 (1996) 149-169
11. Christensen J.Ø., Schultz K., Mollgaard B., Kristensen H.G., and Mullertz A. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur. J. Pharm. Sci. 23 (2004) 287-296
12. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6 (2007) 1001-1018
13. Delie F., Couvreur P., Nisato D., Michel J.B., Puisieux F., and Letourneux Y. Synthesis and in vitro study of a diglyceride prodrug of a peptide. Pharm. Res. 11 (1994) 1082-1087
14. Dissolution assay for solid dosage forms, 2008. Analytical method, European Pharmacopea 6, 2.9.3, 284-294.
15. Drusano L.G., Yuen G.J., Morse G.D., Cooley T.P., Seidlin M., Lambert J.S., Liebman H.A., Valentine F.T., and Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob. Agents Chemother. 36 (1992) 1280-1283
16. Embleton J.K., and Pouton C.W. Structure and function of gastro-intestinal lipases. Adv. Drug Deliv. Rev. 25 (1997) 15-32
17. Folch J., Lees M., Sloane, and Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1957) 497-509
18. Gargouri Y., Moreau H., and Verger R. Gastric lipases: biochemical and physiological studies. Biochim. Biophys. Acta. 1006 (1989) 255-271
19. Garzon-Aburbeh A., Poupaert J.H., Claesen M., and Dumont P. A lymphotropic prodrug of L-DOPA: synthesis, pharmacological properties and pharmacokinetic behaviour of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)-propanoyl]prop ane1,2,3-triol. J. Med. Chem. 29 (1986) 687-691
20. Henneré G., Becher F., Pruvost A., Goujard C., Grassi J., and Benech H. Liquid chromatography-tandem mass spectrometry assays for intracellular deoxyribonucleotide triphosphate competitors of nucleoside antiretrovirals. J. Chromatogr. B 789 (2003) 273-281
21. Huang Y., Zurlinden E., Lin E., Li X., Tokumoto J., Golden J., Murre A., Engstrom J., and Conte. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous determination of didanosine and stavudine in human plasma, bronchoalveolar lavage fluid, alveolar cells, peripheral blood mononuclear cells, seminal plasma, cerebrospinal fluid and tonsil tissue. J. Chromatogr. B 799 (2004) 51-61
22. Jantratid E., Janssen N., Chokshi H., Tang K., and Dressman J.B. Designing biorelevant dissolution tests for lipid formulations: case example-lipid suspension of RZ-50. Eur. J. Pharm. Biopharm 69 (2008) 776-785
23. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162 (1931) 956-959
24. Lalanne M., Paci A., Andrieux K., Dereuddre-Bosquet N., Clayette P., Deroussent A., Ré M., Vassal G., Couvreur P., and Desmaële D. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg. Med. Chem. Lett. 17 (2007) 2237-2240
25. Lalanne M., Andrieux K., Paci A., Besnard M., Ré M., Bourgaux C., Ollivon M., Desmaële D., and Couvreur P. Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. Int. J. Pharm. 344 (2007) 62-70
26. Lambert D.M. Rationale and applications of lipids as prodrug carriers. Eur. J. Pharm. Sci. 11 (2000) S15-S27
27. MacGregor K.J., Embleton J.K., Lacy J.E., Perry E.A., Solomon L.J., Seager H., and Pouton C.W. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv. Drug Deliv. Rev. 25 (1997) 33-46
28. Porter C.J.H., and Charman W.N. Uptake of drugs into the intestinal lymphatics after oral administration. Adv. Drug Deliv. Rev. 25 (1997) 71-89
29. Porter C.J.H., and Charman W.N. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. 50 (2001) 127-147
30. Porter C.J., Trevaskis N.L., and Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6 (2007) 231-248
31. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11 (2000) S93-S98
32. Pruvost A., Negredo E., Benech H., Theodoro F., Puig J., Grau E., Garcia E., Molto J., Grassi J., and Clotet B. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49 (2005) 1907-1914
33. Ransac S., Rogalska E., Gargouri Y., Deveer A.M., Paltauf F., de Haas G.H., and Verger R. Stereoselectivity of lipases I. Hydrolysis of enantiomeric glyceride analogues by gastric and lipases, a kinetic study using the monomolecular film technique. J. Biol. Chem. 265 (1990) 20263-20270
34. Rogalska E., Ransac S., and Verger R. Stereoselectivity of lipases II. Stereoselective hydrolysis of triglycerides by gastric and pancreatic lipases. J. Biol. Chem. 265 (1990) 20271-20276
35. Roisin A., Robin J.P., Dereuddre-Bosquet N., Vitte A.L., Dormont D., Clayette P., and Jalinot P. Inhibition of HIV-1 replication by cell-penetrating peptides binding. Rev. J. Biol. Chem. 279 (2004) 9208-9214
36. Scriba G.K.E. Phenytoin-lipid conjugates: chemical, plasma, esterase-mediated, and pancreatic lipase-mediated hydrolysis in vivo. Pharm. Res. 10 (1993) 1181-1186
37. Tan X., Chu C.K., and Boudinot F.D. Development and optimization of anti-HIV nucleoside analogs and prodrugs: a review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. Adv. Drug Deliv. Rev. 39 (1999) 117-151
38. Yatvin M.B., Li W., Meredith M.J., and Shenoya M.A. Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. Adv. Drug Deliv. Rev. 39 (1999) 165-182